Literature DB >> 32770674

Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia.

Lorenz Rieck1, Frieda Bardey1, Thomas Grenkowitz2, Lars Bertram3,4, Johannes Helmuth5, Claudia Mischung5, Joachim Spranger1, Elisabeth Steinhagen-Thiessen1, Thomas Bobbert1, Ursula Kassner1, Ilja Demuth1,6.   

Abstract

Autosomal-dominant familial hypercholesterolemia (FH) is characterized by increased plasma concentrations of low-density lipoprotein cholesterol (LDL-C) and a substantial risk to develop cardiovascular disease. Causative mutations in three major genes are known: the LDL receptor gene (LDLR), the apolipoprotein B gene (APOB) and the proprotein convertase subtilisin/kexin 9 gene (PCSK9). We clinically characterized 336 patients suspected to have FH and screened them for disease causing mutations in LDLR, APOB, and PCSK9. We genotyped six single nucleotide polymorphisms (SNPs) to calculate a polygenic risk score for the patients and 1985 controls. The 117 patients had a causative variant in one of the analyzed genes. Most variants were found in the LDLR gene (84.9%) with 11 novel mutations. The mean polygenic risk score was significantly higher in FH mutation negative subjects than in FH mutation positive patients (P < .05) and healthy controls (P < .001), whereas the score of the two latter groups did not differ significantly. However, the score explained only about 3% of the baseline LDL-C variance. We verified the previously described clinical and genetic variability of FH for German hypercholesterolemic patients. Evaluation of a six-SNP polygenic score recently proposed for clinical use suggests that it is not a reliable tool to classify hypercholesterolemic patients.
© 2020 The Authors. Clinical Genetics published by John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32770674     DOI: 10.1111/cge.13826

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

1.  Hypercholesterolemia Diagnosis, Treatment Patterns, and 12-Month Target Achievement in Clinical Practice in Germany in Patients with Familial Hypercholesterolemia.

Authors:  Anselm K Gitt; Ulrich Laufs; Winfried März; W Dieter Paar; Peter Bramlage; Nikolaus Marx; Klaus G Parhofer
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

2.  Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia.

Authors:  Akihiro Nomura; Takehiro Sato; Hayato Tada; Takayuki Kannon; Kazuyoshi Hosomichi; Hiromasa Tsujiguchi; Hiroyuki Nakamura; Masayuki Takamura; Atsushi Tajima; Masa-Aki Kawashiri
Journal:  J Hum Genet       Date:  2021-05-10       Impact factor: 3.172

3.  Phenotypic and Genetic Analyses of Korean Patients with Familial Hypercholesterolemia: Results from the KFH Registry 2020.

Authors:  Hyoeun Kim; Chan Joo Lee; Sang-Hyun Kim; Jang Young Kim; Sung Hee Choi; Hyun-Jae Kang; Kyong Soo Park; Byung Ryul Cho; Byung Jin Kim; Ki Chul Sung; In-Kyung Jeong; Jin-Ok Jeong; Jang-Whan Bae; Jung Mi Park; Yunbeom Lee; Ilecheon Jeong; Hyojun Han; Ji Hyun Lee; Sang-Hak Lee
Journal:  J Atheroscler Thromb       Date:  2021-08-30       Impact factor: 4.394

4.  Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.

Authors:  Elena Olmastroni; Marta Gazzotti; Marcello Arca; Maurizio Averna; Angela Pirillo; Alberico Luigi Catapano; Manuela Casula
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.